The Medical Letter on Drugs and Therapeutics
In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
Download PDF:   US English
Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5   doi:10.58347/tml.2023.1668d
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Susan Daron, Pharm D., Associate Editor has disclosed no relevant financial relationships.
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of the furosemide subcutaneous, on-body infusor (Furoscix) for treatment of congestion due to fluid overload in patients with Class II-III chronic heart failure.
 Select a term to see related articles     bumetanide   diuretics   Furoscix   furosemide   heart failure   Lasix   torsemide 

The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.

DIURETICS IN HF — Diuretics can reduce fluid retention in patients with HF, but their effect on survival is unclear. Loop diuretics such as furosemide, bumetanide, and torsemide are more effective than thiazide-type diuretics, such as hydrochlorothiazide, for this indication. Intravenous administration of loop diuretics is often used to achieve rapid diuresis in acute decompensation or to overcome diuretic resistance.1

EFFICACY AND SAFETY — FDA approval of the of the new formulation was based on the results of a study demonstrating that the bioavailability of Furoscix (30 mg SC infusion over 1 hour, followed by 12.5 mg/hour for the next 4 hours) was 99.6% relative to IV furosemide (two 40-mg bolus doses separated by 2 hours) and that it produced equivalent diuresis.2 The most common adverse effects with the SC infusion were administrationsite erythema, bruising, edema, and pain.

An unpublished trial (FREEDOM-HF) in 24 patients presenting to the emergency department with worsening NYHA Class II or III HF compared outpatient use of Furoscix to hospital admission for IV diuresis in 66 matched controls. According to the manufacturer, no patients in the Furoscix group required an initial heart failure hospital admission and 96% of Furoscix-treated patients remained out of the hospital for 30 days after treatment. HF-associated healthcare costs were significantly lower in the Furoscix group.3

DOSAGE, ADMINISTRATION, AND COST — Furoscix should not be used for emergency situations or in patients with acute pulmonary edema. It is also not indicated for chronic use; patients should be switched to oral diuretic therapy as soon as practical.

Furoscix is supplied as a single-use, subcutaneous on-body infusor copackaged with a prefilled cartridge containing an 80 mg/10 mL pH neutral solution of furosemide. The device is pre-programmed to deliver a total of 80 mg of furosemide (30 mg over the first hour, followed by 12.5 mg per hour for the subsequent 4 hours).

After loading the prefilled cartridge into the infusor, the patient should place the device on an area of clean, dry skin on either side of the navel. Pressing the start button on the infusor initiates the subcutaneous infusion. Activity should be limited for the duration of the infusion. The on-body infusor should be kept dry and should not be used within 12 inches of mobile phones, tablets, computers, or wireless accessories. The approximate cost for one on-body infusor and prefilled cartridge is $822.4

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article